Doug Burkett, president of Champions Biotechnology, said: “Studies suggest that our Biomerk Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
“A growing number of pharmaceutical and biotechnology companies are beginning to recognize the predictive potential of Biomerk Tumorgrafts. Centocor has an impressive track record in the research, development, and commercialization of human therapeutic agents and we are delighted to enter into these agreements with the company.”